Last Updated: May 25, 2026

CLINICAL TRIALS PROFILE FOR INCIVEK


✉ Email this page to a colleague

« Back to Dashboard


505(b)(2) Clinical Trials for Incivek

This table shows clinical trials for potential 505(b)(2) applications. See the next table for all clinical trials
Trial Type Trial ID Title Status Sponsor Phase Start Date Summary
New Formulation NCT01511432 ↗ A Study to Assess the Relative Bioavailability Three New Formulations of Telaprevir in Healthy Subjects Completed Vertex Pharmaceuticals Incorporated Phase 1 2012-01-01 The purpose of this study is to evaluate the relative bioavailability, safety, and tolerability of 3 new formulations of telaprevir relative to the Incivek 375-mg tablets.
>Trial Type >Trial ID >Title >Status >Phase >Start Date >Summary

All Clinical Trials for Incivek

Trial ID Title Status Sponsor Phase Start Date Summary
NCT01355289 ↗ Chronic Hepatitis C Virus Related Thrombocytopenia to Evaluate the Effects of E5501 Completed Eisai Inc. Phase 2 2011-11-01 To evaluate the efficacy of E5501 by measuring platelet response in subjects with chronic hepatitis C virus (HCV)-related thrombocytopenia who require antiviral treatment.
NCT01459913 ↗ Efficacy of a 12-Week Regimen of Telaprevir, Pegylated Interferon, and Ribavirin in Treatment-Naive and Prior Relapser Subjects With Interleukin28B (IL28B) CC Genotype Terminated Vertex Pharmaceuticals Incorporated Phase 3 2011-11-01 The purpose of this study is to evaluate if a 12-week total regimen of telaprevir in combination with pegylated interferon alfa 2a (Peg-IFN-alfa-2a) and ribavirin (RBV) (T12/PR12) is safe and effective in subjects who have the interleukin-28B (IL28B) CC genotype. The subjects enrolled in this study will have chronic hepatitis C virus (HCV) infection and will not have cirrhosis of the liver.
NCT01511432 ↗ A Study to Assess the Relative Bioavailability Three New Formulations of Telaprevir in Healthy Subjects Completed Vertex Pharmaceuticals Incorporated Phase 1 2012-01-01 The purpose of this study is to evaluate the relative bioavailability, safety, and tolerability of 3 new formulations of telaprevir relative to the Incivek 375-mg tablets.
>Trial ID >Title >Status >Phase >Start Date >Summary

Clinical Trial Conditions for Incivek

Condition Name

Condition Name for Incivek
Intervention Trials
Hepatitis C 3
Hepatitis C, Chronic 3
Chronic Hepatitis C 2
[disabled in preview] 1
This preview shows a limited data set
Subscribe for full access, or try a Trial

Condition MeSH

Condition MeSH for Incivek
Intervention Trials
Hepatitis C 11
Hepatitis 10
Hepatitis A 7
[disabled in preview] 1
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Locations for Incivek

Trials by Country

Trials by Country for Incivek
Location Trials
United States 60
Canada 8
Brazil 5
Russian Federation 2
Germany 2
This preview shows a limited data set
Subscribe for full access, or try a Trial

Trials by US State

Trials by US State for Incivek
Location Trials
Texas 6
California 5
Virginia 4
Wisconsin 3
Pennsylvania 3
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Progress for Incivek

Clinical Trial Phase

Clinical Trial Phase for Incivek
Clinical Trial Phase Trials
Phase 4 2
Phase 3 3
Phase 2/Phase 3 1
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Status

Clinical Trial Status for Incivek
Clinical Trial Phase Trials
Completed 6
Terminated 3
Withdrawn 2
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Sponsors for Incivek

Sponsor Name

Sponsor Name for Incivek
Sponsor Trials
Vertex Pharmaceuticals Incorporated 5
Santaris Pharma A/S 2
University of Chicago 1
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Sponsor Type

Sponsor Type for Incivek
Sponsor Trials
Industry 9
Other 4
U.S. Fed 1
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

INCIVEK (telaprevir) clinical trials update, market analysis, and exclusivity-driven projection

Last updated: May 23, 2026

INCIVEK (telaprevir) is a discontinued, direct-acting antiviral (DAA) for chronic hepatitis C (HCV) that entered the market in 2011 and rapidly became obsolete as pan-genotypic regimens using NS5A inhibitors and improved NS3 protease inhibitor combinations took over. Telaprevir is no longer the standard of care, and current “market projection” is a residual view of (1) remaining demand from historic treatment protocols, (2) supply-chain carryover, and (3) generics/therapeutic substitutes rather than new brand growth.

What is INCIVEK (telaprevir) and where does it sit in the HCV treatment sequence?

INCIVEK is telaprevir, an NS3/4A protease inhibitor for chronic HCV, used in combination with peginterferon alfa and ribavirin in earlier DAA regimens. Its clinical role is largely historical because later regimens reduced dependence on interferon and improved cure rates with simpler dosing.

Which patient populations were telaprevir-based regimens designed for?

Telaprevir regimens were developed and labeled around:

  • Treatment-naïve adults with chronic genotype 1 HCV
  • Prior “null responder,” “partial responder,” and “relapser” cohorts under earlier interferon-based standards
  • Liver disease severity stratification relevant to early DAA adoption

How does telaprevir compare with modern pan-genotypic DAAs?

Telaprevir-era therapy:

  • Required peginterferon and ribavirin backbone
  • Was genotype-restricted (predominantly genotype 1)
  • Used a protease-inhibitor backbone that was superseded by newer NS3 protease inhibitors used in fixed combinations with NS5A inhibitors

Modern therapy:

  • Uses pan-genotypic or broader-genotype regimens
  • Is largely interferon-free
  • Has higher tolerability and simpler patient management

What clinical trial milestones defined telaprevir’s efficacy and safety profile?

INCIVEK’s clinical evidence came from Phase 2 and Phase 3 studies that established sustained virologic response (SVR) improvements when telaprevir was added to peginterferon alfa and ribavirin. The key commercial relevance is that the evidence underpinned rapid initial adoption and payer coverage, then quickly lost relevance as improved fixed-dose combinations emerged.

Which efficacy endpoints drove INCIVEK’s Phase 3 positioning?

The principal endpoint across pivotal programs was SVR, typically measured as:

  • SVR12 (HCV RNA undetectable 12 weeks after treatment), which became the practical standard endpoint during that era

What adverse events shaped prescribing constraints?

Telaprevir’s safety profile mattered commercially because it affected:

  • Hematologic tolerability (ribavirin and interferon interactions)
  • Dermatologic risk monitoring (rash management under triple therapy protocols)
  • Drug-drug interaction management, given protease inhibitor class behavior

When does INCIVEK lose exclusivity, and what does that imply for remaining supply?

INCIVEK’s brand exclusivity has long passed in major markets. Current availability is predominantly generic and/or therapeutically replaced. Any residual “exclusivity timeline” is therefore relevant mostly for:

  • Understanding which geographies still have any branded inventory
  • Mapping generic life-cycle transitions for telaprevir molecules, not for new indications

Practical projection implication: new patient starts under telaprevir-based protocols are minimal, so market outlook is a function of substitution patterns rather than formal exclusivity.

What patents protect telaprevir (INCIVEK) and how strong is the estate now?

Patent estates for older HCV DAAs often bifurcate into:

  • Primary composition-of-matter coverage (early 2000s filings for the molecule class)
  • Formulation and method-of-use claims (interferon combination regimens, dosing schedules, supportive manufacturing claims)

Practical outcome: for telaprevir, the molecule has been on the market since the early DAA cycle, so enforceable patent life against generic entry has largely expired or been resolved historically. The active risk today is not new Paragraph IV filings but remaining litigation outcomes already settled and how quickly generics entrenched.

What is the Orange Book status of INCIVEK (telaprevir)?

INCIVEK is not expected to have active brand exclusivity or ongoing brand-relevant listings today. In practice, Orange Book status for telaprevir historically reflected:

  • An original NDA with accompanying listed patents
  • Generics relying on patent expiration and/or earlier challenges

Commercial relevance: today’s competitive landscape is primarily generic telaprevir and therapy switching to newer DAA combinations.

Which companies sell telaprevir generically and what is the competitive landscape?

Telaprevir’s current market is dominated by:

  • Generic telaprevir manufacturers in markets where telaprevir remains commercially available
  • Healthcare provider preference shifts toward modern DAAs, limiting telaprevir penetration

Key competitive dynamic: the limiting factor is not generic capacity or price alone. It is clinical guideline movement away from telaprevir triple-therapy frameworks.

What generic entry risks existed for telaprevir and Paragraph IV outcomes mattered?

For historical context:

  • Generic entry risks centered on Orange Book patents tied to telaprevir
  • Paragraph IV certifications determined entry timing and often forced settlements

Today’s relevance: telaprevir is an established molecule with a legacy patent resolution history. The “generic entry risk” in the sense of new challenges is low; current pressure comes from market substitution to newer fixed-dose DAAs rather than legal entry barriers.

How does telaprevir market performance compare with successor DAAs?

Telaprevir’s peak adoption occurred during early interferon-era DAA expansion. Its volume then contracted as:

  • Better tolerated regimens replaced triple therapy
  • Pan-genotypic, interferon-free standards became preferred
  • Fixed-dose combination products simplified dosing and monitoring

Market analysis implication: telaprevir revenue followed a typical early DAA diffusion curve: sharp uptake in the initial DAA window, then fast erosion due to therapeutic displacement.

Market analysis: drivers of INCIVEK demand in 2026

Demand drivers

  • Historical patient cohorts needing regimen continuity in limited settings
  • Availability constraints in certain regional formularies
  • Price-based procurement where payers still allow telaprevir historically

Demand dampeners

  • Guideline displacement to interferon-free and pan-genotypic DAAs
  • Clinical practice preference for shorter, simpler regimens with better tolerability
  • Reduced prescriber incentive to manage protease-inhibitor triple therapy protocols

What is the residual addressable market (RAM)?

The RAM for telaprevir is best modeled as:

  • A shrinking base of legacy regimen usage
  • Minus a larger portion of patient starts switching to modern alternatives

Projection direction: declining, with the steepest decline already realized years earlier.

Commercial projection for INCIVEK: base case, downside, upside

Because telaprevir is displaced by modern DAAs, the projection logic is not “growth,” it is “residual decline and stabilization.”

Base case (most likely)

  • Continued low single-digit or less percentage share of total HCV DAA starts
  • Mostly generic erosion pushing prices down, with volume stable only where telaprevir remains on formulary

Downside case

  • Faster guideline adoption at regional level
  • Greater formulary exclusion as newer DAAs expand
  • Supply consolidation that reduces ability to procure telaprevir in certain countries

Upside case

  • Regional payer retention of interferon-era DAAs due to procurement contracts
  • Short-term inventory pull-through of generics where telaprevir remains an option

Net: negative trajectory by volume; revenue depends on generic price levels and residual access.

What regulatory changes affected telaprevir’s commercial viability?

Key regulatory dynamics that matter commercially in DAAs generally include:

  • Safety communications during the interferon-era DAA period
  • Label updates tied to resistance monitoring and genotype/ribavirin rules
  • Competition-driven withdrawal dynamics as newer regimens gained approvals

For telaprevir specifically, regulatory viability is dominated today by the lack of renewed clinical adoption rather than by fresh regulatory barriers.

What is the litigation landscape for telaprevir patents and HCV DAA combinations?

Telaprevir’s litigation history belongs largely to the early generic entry era:

  • Orange Book patent disputes
  • Settle-and-launch patterns tied to patent expiry dates
  • Cross-licensed disputes around DAAs broadly (NS3 protease inhibitors and fixed combination advancements)

Current stance: litigation is not expected to be a primary determinant of telaprevir’s market trajectory in 2026. Substitution is.

How does INCIVEK compare with other NS3 protease inhibitors and HCV DAAs?

Telaprevir compares with newer NS3 protease inhibitor successors by:

  • Fixed-dose combination architectures
  • Interferon-free regimens
  • Wider genotype coverage and improved resistance management

This is the structural reason telaprevir’s market compressed quickly.

Key Takeaways

  • INCIVEK (telaprevir) is a legacy genotype-1 NS3/4A protease inhibitor from the interferon-era triple-therapy period.
  • Clinical evidence supported strong SVR outcomes at launch, but telaprevir was rapidly displaced by interferon-free, pan-genotypic DAA combinations.
  • Exclusivity and patent-driven barriers are largely historical; the present-day market is governed by generic substitution and clinical guideline displacement.
  • 2026 market outlook is residual and shrinking, driven by low remaining patient starts rather than active brand competition or imminent regulatory/patent inflection.

FAQs

  1. Why did telaprevir-based therapy decline so quickly after approval?
  2. Are there any countries where INCIVEK remains a meaningful formulary option?
  3. Do telaprevir generics face any ongoing patent or regulatory constraints in 2026?
  4. How do telaprevir’s safety management requirements compare with modern DAAs?
  5. What resistant variants were a concern with telaprevir and how did that affect regimen use?

References

  1. APA: FDA. Drug approvals and labeling archives for telaprevir (INCIVEK). U.S. Food and Drug Administration.
  2. APA: FDA. Orange Book: Approved Drug Products with Therapeutic Equivalence Evaluations for telaprevir-containing products. U.S. Food and Drug Administration.
  3. APA: Published clinical trial reports on telaprevir in chronic hepatitis C (Phase 2/3 studies; SVR endpoint publications). Peer-reviewed journal literature.

More… ↓

⤷  Start Trial

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. We do not provide individual investment advice. This service is not registered with any financial regulatory agency. The information we publish is educational only and based on our opinions plus our models. By using DrugPatentWatch you acknowledge that we do not provide personalized recommendations or advice. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.